Joint with: Drug Delivery to the Brain: Emerging Modalities
Antibodies as Drugs: Innovative Formats, Design and Engineering
Feb 17–20, 2025 | Keystone Resort, Keystone, CO, United States
Scientific Organizers:
Jean-Philippe Julien and Katherine Harris
In Person
On Demand
Feb 17–20, 2025 | Keystone Resort, Keystone, CO, United States
Scientific Organizers:
Jean-Philippe Julien and Katherine Harris
Available Formats:
Supported by:
In Person
On Demand
***Meeting program subject to change.
Available Formats: = In Person = On DemandMonday, February 17, 2025
Fundraising
Booking Function
Merchandise Options
Registration Options
Registration
4:00–8:00 PM
Longs Peak Foyer
Welcome Mixer
6:00–8:00 PM
Longs Peak Foyer
Tuesday, February 18, 2025
Breakfast
7:00–8:00 AM
Shavano/Torreys/Red Cloud
Welcome and Keynote Address
8:00–9:00 AM
Grays Peak
* Katherine Harris, Rondo Therapeutics
Session Chair
Session Chair
* Jean-Philippe Julien, Hospital for Sick Children Research Institute
Session Chair
Session Chair
Koustubh Ranade, Immunocore
Monoclonal Antibodies & TCRs: Shaping the Future of Therapeutic Design
Monoclonal Antibodies & TCRs: Shaping the Future of Therapeutic Design
Antibody-Based Protein Degraders for Therapeutics Development
9:00–11:00 AM
Grays Peak
Leo James, MRC Laboratory of Molecular Biology
Remote Presentation: Trim-Away: TRIM21-based Modalities for Intracellular Targeted Protein Degradation
Remote Presentation: Trim-Away: TRIM21-based Modalities for Intracellular Targeted Protein Degradation
Jithu Krishna, University of Massachusetts, Amherst
Short Talk: Polymeric Lysosomal-Targeting Chimeras: Extracellular Targeted Protein Degradation Without Co-opting Lysosome-Targeting Receptors
Short Talk: Polymeric Lysosomal-Targeting Chimeras: Extracellular Targeted Protein Degradation Without Co-opting Lysosome-Targeting Receptors
* James A Wells, University of California, San Francisco
Novel Approaches for Extracellular Targeted Protein Degradation (eTPD)
Novel Approaches for Extracellular Targeted Protein Degradation (eTPD)
Coffee Break
9:30–9:50 AM
Longs Peak Foyer
Poster Setup
11:15–1:00 PM
Shavano/Torreys/Red Cloud
On Own for Lunch
11:15–5:00 PM
Poster Viewing
1:00–10:00 PM
Shavano/Torreys/Red Cloud
Symposia Spotlight 1: Preclinical Development of Antibody Therapeutics: From Discovery to IND
1:30–3:30 PM
Grays Peak
* Kirstin A Zettlitz, Beckman Research Institute of the City of Hope
Fc-engineering to Increase the Therapeutic Index for Antibody Fragment-based Radioimmunotherapy
Fc-engineering to Increase the Therapeutic Index for Antibody Fragment-based Radioimmunotherapy
Daniela Cipolletta, Seismic Therapeutic
S-4321, A Novel Dual-cell Bidirectional PD-1:FcγRIIb Selective Agonist Antibody for the Treatment of Autoimmune Disease
S-4321, A Novel Dual-cell Bidirectional PD-1:FcγRIIb Selective Agonist Antibody for the Treatment of Autoimmune Disease
Cory Brooks, California State University, Fresno
Targeting MUC16 in Pancreatic Cancer: Structural and Functional Analysis of the Humanized AR9.6 Antibody
Targeting MUC16 in Pancreatic Cancer: Structural and Functional Analysis of the Humanized AR9.6 Antibody
Gualberto G. Gonzalez-Sapienza, Facultad de Quimica, UdelaR
Targeting PD-L1 Blockade to Dendritic Cells through Simultaneous Binding to CD11c Enhances Antitumor Efficacy
Targeting PD-L1 Blockade to Dendritic Cells through Simultaneous Binding to CD11c Enhances Antitumor Efficacy
Melanie Walker, RenBio
Development of an Influenza Neutralizing Antibody Cocktail using DNA-based Delivery
Development of an Influenza Neutralizing Antibody Cocktail using DNA-based Delivery
Stefan Schmidt, Evitira AG
Trans-splicing Mediated Recombination to Generate Multi-specific Antibodies
Trans-splicing Mediated Recombination to Generate Multi-specific Antibodies
Isabel Grace Elliott, University of Southampton
Structure-guided Disulfide Engineering Restricts Antibody Conformation to Elicit TNFR Agonism in Anti-cancer Therapeutics
Structure-guided Disulfide Engineering Restricts Antibody Conformation to Elicit TNFR Agonism in Anti-cancer Therapeutics
Career Roundtable (Joint)
3:30–4:30 PM
Grays Peak
Luka Kulic, F. Hoffmann-La Roche Ltd.
Therapeutic Area Leader Dementias, Expert Scientist and Medical Director
Therapeutic Area Leader Dementias, Expert Scientist and Medical Director
Kylie Chew, Denali Therapeutics
Principal Scientist
Principal Scientist
Russell K Pachynski, Washington University in St. Louis
Associate Professor
Associate Professor
Roosmarijn E Vandenbroucke, VIB and Ghent University
Group Leader & Professor
Group Leader & Professor
Coffee Available
4:30–5:00 PM
Longs Peak Foyer
New Developments in Antibody Drug Conjugate Technology
5:00–6:45 PM
Grays Peak
Seema Kantak, Exelixis
Discovery of XB010, a Next Generation 5T4-targeting ADC
Discovery of XB010, a Next Generation 5T4-targeting ADC
Scott Lesley, InduPro
Proximity-based Bispecific Antibody Strategies to Address Disease
Proximity-based Bispecific Antibody Strategies to Address Disease
Cocktail Hour Sponsored by Nicoya
7:00–8:00 PM
Shavano/Torreys/Red Cloud
Dinner
7:05–8:05 PM
Shavano/Torreys/Red Cloud
Poster Session 1
7:30–10:00 PM
Shavano/Torreys/Red Cloud
Wednesday, February 19, 2025
Breakfast
7:00–8:00 AM
Shavano/Torreys/Red Cloud
Pushing the Boundaries of Biologics Towards Precision
8:00–11:00 AM
Grays Peak
Benjamí Oller-Salvia, Ramon Llull University
Novel Approaches for Conditionally-Active and Brain-Permeable Antibodies
Novel Approaches for Conditionally-Active and Brain-Permeable Antibodies
* Mark S Cragg, University of Southampton
Developing Immunostimulating Antibodies to Deliver Agonism Without Toxicity
Developing Immunostimulating Antibodies to Deliver Agonism Without Toxicity
Marvin Gee, 3T Biosciences
TCR Biologics
TCR Biologics
David G Kugler, Cartography Biosciences
Identifying & Building Around Optimal Targets for Oncology Therapies
Identifying & Building Around Optimal Targets for Oncology Therapies
Vanessa Laversenne, Broad Institute of Harvard and MIT
Short Talk: Evaluating Peripheral Delivery of Anti-PrP Antibody AZ59 for Brain PrP Targeting and Therapeutic Potential in Prion Disease
Short Talk: Evaluating Peripheral Delivery of Anti-PrP Antibody AZ59 for Brain PrP Targeting and Therapeutic Potential in Prion Disease
Constantinos_Kurt Wibmer, Wits Health Consortium
Short Talk: A Monoclonal Antibody that Neutralizes both Long- and Short-chain Three Finger Snake Venom Neurotoxins
Short Talk: A Monoclonal Antibody that Neutralizes both Long- and Short-chain Three Finger Snake Venom Neurotoxins
Coffee Break
9:00–9:20 AM
Longs Peak Foyer
Award Recipient Acknowledgement
9:20–9:25 AM
Grays Peak
On Own for Lunch
11:00–5:00 PM
Coffee Available
4:30–5:00 PM
Longs Peak Foyer
Technologies to Increase Drug Accessibility against Infectious Diseases on a Global Scale
5:00–7:00 PM
Grays Peak
Semiramis Yilmaz, VIB-UGent Center for Medical Biotechnology
A Yeast Manufacturing Platform for VHH-Fc Type Molecules
A Yeast Manufacturing Platform for VHH-Fc Type Molecules
Anja F Hohmann, Be Biopharma
Genetically Engineered B Cell Medicines for Sustained in Vivo Delivery of Therapeutic Biologics
Genetically Engineered B Cell Medicines for Sustained in Vivo Delivery of Therapeutic Biologics
* Christopher O Barnes, Stanford University
Antibody Therapeutics Against Respiratory RNA Viruses
Antibody Therapeutics Against Respiratory RNA Viruses
Jean-Philippe Julien, Hospital for Sick Children Research Institute
Antibody-based Strategies to Block the Transmission of Malaria
Antibody-based Strategies to Block the Transmission of Malaria
Social Hour with Lite Bites
7:00–8:00 PM
Shavano/Torreys/Red Cloud
Poster Session 2
7:30–10:00 PM
Shavano/Torreys/Red Cloud
Thursday, February 20, 2025
Breakfast
7:00–8:00 AM
Shavano/Torreys/Red Cloud
Therapeutic Applications of Fc Domain Engineering
8:00–10:30 AM
Grays Peak
* E. Sally Ward, University of Southampton
Targeting FcRn for the Generation of Therapeutics for Antibody-Mediated Disease
Targeting FcRn for the Generation of Therapeutics for Antibody-Mediated Disease
John R. Desjarlais, Xencor, Inc.
Optimization and Application of Fc-Containing Bispecific Antibodies
Optimization and Application of Fc-Containing Bispecific Antibodies
Karen Silence, arGEN-X BVBA
Engineering of Antibodies for Optimal FcRn Engagement
Engineering of Antibodies for Optimal FcRn Engagement
Ibo Janssens, Argenx
Short Talk: How Format Impacts Activity: Structure-activity Relationship for Optimal FcRn Engagement of Fc-based Therapeutics
Short Talk: How Format Impacts Activity: Structure-activity Relationship for Optimal FcRn Engagement of Fc-based Therapeutics
Stefan Weise, Roche Diagnostics GmbH
Short Talk: Structure-PK Relationship: Complex Antibody Format Affects Pharmacokinetic Properties via FcRn Recycling
Short Talk: Structure-PK Relationship: Complex Antibody Format Affects Pharmacokinetic Properties via FcRn Recycling
Coffee Break
9:00–9:20 AM
Longs Peak Foyer
On Own for Lunch
11:00–5:00 PM
Symposia Spotlight 2: Leveraging AI and ML in Antibody Discovery, Engineering and Beyond
2:30–4:30 PM
Grays Peak
Joel Bard, Pfizer
Biocheminformatics – Enabling Data Science for Macromolecular Drug Discovery
Biocheminformatics – Enabling Data Science for Macromolecular Drug Discovery
* Karen Duffy, Manifold Bio
Integrating High-throughput in vivo Screening with AI-guided Protein Design to Select Brain Shuttles with Optimal Pharmacokinetics, Biodistribution, and Other Drug-like Properties
Integrating High-throughput in vivo Screening with AI-guided Protein Design to Select Brain Shuttles with Optimal Pharmacokinetics, Biodistribution, and Other Drug-like Properties
Nitesh Mishra, The Scripps Research Institute
Rapid AI-Driven Design of Broadly Neutralizing Antibodies Targeting the HIV-1 Envelope Glycoprotein
Rapid AI-Driven Design of Broadly Neutralizing Antibodies Targeting the HIV-1 Envelope Glycoprotein
Sameer Soi, Abalone Bio
Harnessing Protein Language Models and Large-Scale Functional Data to Generate Novel, Functionally Active Antibody Therapeutics
Harnessing Protein Language Models and Large-Scale Functional Data to Generate Novel, Functionally Active Antibody Therapeutics
Ariel Tennenhouse, Weizmann Institute of Science
One-shot Optimization of Antibody Developability and Affinity by Computational Design
One-shot Optimization of Antibody Developability and Affinity by Computational Design
* Peter Tessier, University of Michigan
Optimization of Mono- and Multi-Specific Antibodies Using Machine Learning and Atomistic Design
Optimization of Mono- and Multi-Specific Antibodies Using Machine Learning and Atomistic Design
Greg Mirando, Precision BioTools
Targeting KRAS Mutation Diversity with Epivolve®: A Novel Approach for Precision Cancer Therapeutics and Diagnostics
Targeting KRAS Mutation Diversity with Epivolve®: A Novel Approach for Precision Cancer Therapeutics and Diagnostics
Deborah Flusberg, Certara
Mechanistic Modeling Guides Bispecific Antibody Design and Target Selection for Maximizing Therapeutic Window
Mechanistic Modeling Guides Bispecific Antibody Design and Target Selection for Maximizing Therapeutic Window
Coffee Available
4:30–5:00 PM
Longs Peak Foyer
Novel Antibody Therapies and Combinations
5:00–6:45 PM
Grays Peak
Rony Dahan, Weizmann Institute of Science
Bispecific Immune Synapse Engagers for Cancer Immunotherapy
Bispecific Immune Synapse Engagers for Cancer Immunotherapy
Katherine Harris, Rondo Therapeutics
Bispecific Antibody Combination Strategies for Treating Solid Tumors
Bispecific Antibody Combination Strategies for Treating Solid Tumors
* Katherine Cygnar, Regeneron Pharmaceuticals
Optimizing BBB-Crossing Antibodies and Antibody-Targeted Cargo
Optimizing BBB-Crossing Antibodies and Antibody-Targeted Cargo
Mike Wan, Gilead Science
Short Talk: Utilizing Cis-binding in T Cell Engagers: Theoretical Modeling to Guide 2+1 and Multi-specific TCE Design
Short Talk: Utilizing Cis-binding in T Cell Engagers: Theoretical Modeling to Guide 2+1 and Multi-specific TCE Design
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Grays Peak
Social Hour with Lite Bites
7:00–8:00 PM
Shavano/Torreys/Red Cloud
Entertainment
8:00–9:00 PM
Longs Peak
Cash Bar
8:00–9:00 PM
Shavano/Torreys/Red Cloud
Friday, February 21, 2025
Departure
12:00–11:59 PM
Subscribe for Updates